SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

NanoVibronix Inc

NAOV is trending due to renewed interest in low float stocks and recent news regarding a patent and an agreement with a New York medical center. The community is discussing its potential for a significant squeeze, citing the limited float and high short interest. Some traders are comparing it to other recently successful low-float runners.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is experiencing significant volatility, with community chatter focused on potential pump-and-dump schemes and short squeeze opportunities. Speculation around upcoming news and potential for a crypto treasury strategy, similar to other trending tickers, are driving interest. Some traders caution about the company's history and potential risks, while others remain optimistic about a potential surge.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending amidst discussions around its high short interest, potential for a short squeeze, and the upcoming launch of its Rumble Wallet. Some see the stock as a play on a shift in media and cloud services towards platforms valuing free speech, further fueled by the perceived support from prominent figures. Additionally, the possible acquisition of Northern Data and its impact on Rumble's cloud capacity is a hot topic.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid discussions around potential short squeezes and participation in air taxi pilot programs, with community members weighing the stock's technical indicators and comparing it to sector peers like Joby Aviation. Some investors express bullish sentiment, citing potential catalysts and government support, while others remain cautious, pointing to bearish signals and concerns over execution. The community is also actively debating the impact of recent news and potential partnerships.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

LVLU is trending due to a potential short squeeze, with community members pointing to its low float and high insider ownership. Some traders are taking profits from other recent runners like $CHEK and $HSDT and moving them into LVLU. The stock experienced a halt and is seeing increased volume, leading to speculation about a significant move.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors react to news of Elon Musk's $1 billion purchase of TSLA shares, his first buy since 2020, which the community sees as a strong confidence signal.  Discussions revolve around potential short squeezes and the impact on the stock's valuation, with some questioning fundamentals while others anticipate further gains.  The move occurs amid ongoing conversations about Tesla's role in the EV market and Musk's broader ventures.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics is trending after announcing a licensing agreement with Novartis worth up to $5.7 billion, sparking significant community discussion around the company's valuation and potential buyout. Bullish investors are targeting much higher price points, while others are wary of a potential pullback after the surge. The community is closely watching the low float and the implications of the deal for the company's future.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors assess its long-term potential following a recent dip, despite strong fundamentals and a monopoly in EUV lithography. Community discussions revolve around the impact of potential tariffs, the company's relationship with key players like Intel and TSMC, and its strategic role in the AI-driven semiconductor industry. Some analysts are pointing to an attractive entry point for the stock.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is experiencing volatility as investors digest news of a $150 million mixed shelf offering, sparking discussions about dilution and debt management; despite solid earnings and raised guidance. Bullish community members view it as a buying opportunity, anticipating long-term growth and potential rate cuts, while others express concern about the timing and communication surrounding the offering.

PennyMac Financial Services, Inc. is a holding company, which engages in the production and servicing of U.S. residential mortgage loans. It operates through the following segments: Loan Production, Loan Servicing, and Investment Management. The Loan Production segment is sourced through three channels: correspondent production, consumer direct lending, and broker direct lending. The Loan Servicing segment performs loan administration, collection, and default management activities. The Investment Management segment currently manages PennyMac Mortgage Investment Trust. The company was founded by Stanford L. Kurland on July 2, 2008 and is headquartered in Westlake Village, CA.

PennyMac Financial Services Inc.

PFSI is trending as investors discuss the mortgage industry and potential impacts from rising rates. Community members are weighing the company's financial health and future prospects in a changing economic environment. Discussions include analyst ratings and price target adjustments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics. Click here to learn how to join our...

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today's pre-market trading following fourth-quarter results.
read more...

Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
read more...

12 titoli sanitari in movimento, after-market del 22/03/2024

Titoli in rialzo
Le azioni di Salarius Pharmaceuticals (NASDAQ:SLRX) sono cresciute del 33,90% a 0,83 dollari durante la sessione after-market di venerd .
Il titolo Masimo (NASDAQ:MASI) ha osservato...

12 acciones de salud en movimiento en la subasta de cierre del 22/03/2024

Acciones al alza
Salarius Pharmaceuticals (NASDAQ:SLRX) experimentaron un repunte del 35,29% para establecerse en los 0,84 d lares durante la sesi n del after-market del viernes.
Masimo (NASDAQ:MASI...

Salarius Pharmaceuticals GAAP EPS of -$3.84

Salarius Pharmaceuticals GAAP EPS of -$3.84...

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Company implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from...

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan...

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and...

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

SLRX
Salarius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLRX News

SLRX Salarius Pharmaceuticals Inc